A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in subjects with advanced non–small cell lung cancer.
2014 ◽
Vol 32
(15_suppl)
◽
pp. e19137-e19137
◽
Keyword(s):
2016 ◽
Vol 34
(15_suppl)
◽
pp. e20659-e20659
◽
Keyword(s):
2008 ◽
Vol 26
(15_suppl)
◽
pp. 19002-19002
Keyword(s):
2008 ◽
Vol 26
(15_suppl)
◽
pp. 8025-8025
◽
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. TPS290-TPS290
◽
Keyword(s):
Keyword(s):
2008 ◽
Vol 26
(15_suppl)
◽
pp. 19012-19012
Keyword(s):